Assessment of the Clinical Utility of the NETest in a US Registry-Based Study

#2202

Introduction: The clinical relevance of molecular biomarkers in oncology management has been recognized in breast and lung cancer. Current biomarkers in NET disease have limited clinical utility.

Aim(s): We evaluated the usefulness of a blood-based multigene biomarker assay in the management of neuroendocrine tumor disease (NETs) in a real-world study of a USA registry (RegisterNET: NCT02270567) of 100 patients. The NET liquid biopsy was investigated for diagnostic accuracy, and prediction of clinical disease status in 2 cohorts (treated and watch-and-wait).

Materials and methods: NET subjects (n=100) followed for 6 months. Gastroenteropancreatic (68%); lung 20%, and unknown origin (12%).Well-differentiated, low grade (97%), stage IV (96%); 70% had surgery; 56% drug treatment. NETest was measured at each visit and disease status was determined by RECIST. Scores categorized as low (NETest <40%) or high (>80%) defined disease as stable or progressive.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Bodei L

Authors: Liu E, Paulson S, Gulati A, Freudman J, Grosh W,

Keywords: Registry, biomarker, NETest, GEP-NET, Monitor, Treatment, Predict,

To read the full abstract, please log into your ENETS Member account.